SPOTLIGHT -
Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer
Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Read More
Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC
Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).
Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer
Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)